Funding
Hepa Wash GmbH has announced the closing of its first financing round, raising €3.8 million from a syndicate of new and existing private investors, allowing the company to advance its liver support machine into clinical studies in spring 2010.
Bernhard Kreymann, CEO, said, “Despite the very difficult economical situation we were able to attract a highly distinguished group of long-term committed private investors [who are] experienced in the medical device sector.”
The Hepa Wash therapy has been successfully tested in two preclinical studies, underpinning the further development of the device. “Hopefully, in 2011 we will have a new proven treatment to reduce the very high death rate of liver patients on the intensive care unit,” Kreymann said.
Hepa Wash, of Munich, was founded in 2004 and received initial funding from private investors as well as grants from the Bavarian Endowment for Research (Bayerische Forschungsstiftung) and the Bavarian State Office for Economics (Bayerisches Staatsministeriums für Wirtschaft, Infrastruktur, Verkehr und Technologie).
Receive the Funding Newswire each Tuesday, our Policy Bulletin each Thursday, and news about bridging Europe’s east-west innovation gap twice a month in The Widening. 
A unique international forum for public research organisations and companies to connect their external engagement with strategic interests around their R&D system.
